A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease

Autor: Hardin, M, Cho, MH, McDonald, M-L, Wan, E, Lomas, DA, Coxson, HO, MacNee, W, Vestbo, J, Yates, JC, Agusti, A, Calverley, PMA, Celli, B, Crim, C, Rennard, S, Wouters, E, Bakke, P, Bhatt, SP, Kim, V, Ramsdell, J, Regan, EA, Make, BJ, Hokanson, JE, Crapo, JD, Beaty, TH, Hersh, CP, ECLIPSE and COPDGene Investigators, COPDGene Investigators—clinical centers

Publikováno v: The pharmacogenomics journal, vol 16, iss 4

Short-acting β2-agonist bronchodilators are the most common medications used in treating chronic obstructive pulmonary disease (COPD). Genetic variants determining bronchodilator responsiveness (BDR) in COPD have not been identified. We performed a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::524f5c70b5e519c22edc3e8d2166f3e6
https://escholarship.org/uc/item/1hz62367

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.

Autor: Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B, Ferguson, Gary T, Calverley, Peter M A, Anderson, Julie A, Jenkins, Christine R, Jones, Paul W, Willits, Lisa R, Yates, Julie C, Vestbo, Jørgen, Celli, Bartolome

Publikováno v: CHEST; Dec2009, Vol. 136 Issue 6, p1456-1465, 10p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.

Autor: Celli B; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Joint first authors., Locantore N; GSK R&D, Collegeville, PA, USA.; Joint first authors., Yates JC; GSK R&D, Research Triangle Park, NC, USA., Bakke P; Institute of Internal Medicine, University of Bergen, Bergen, Norway., Calverley PMA; Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK., Crim C; GSK R&D, Research Triangle Park, NC, USA., Coxson HO; Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada., Lomas DA; UCL Respiratory, Rayne Institute, University College London, London, UK., MacNee W; University of Edinburgh, Edinburgh, UK., Miller BE; GSK R&D, Collegeville, PA, USA., Mullerova H; GSK R&D, Collegeville, PA, USA., Rennard SI; University of Nebraska Medical Center, Omaha, NE, USA., Silverman EK; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Wouters E; University of Maastricht, Maastricht, The Netherlands.; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria., Tal-Singer R; GSK R&D, Collegeville, PA, USA., Agusti A; Respiratory Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.; CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.; Joint senior authors., Vestbo J; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, UK.; Joint senior authors.

Publikováno v: The European respiratory journal [Eur Respir J] 2021 Mar 25; Vol. 57 (3). Date of Electronic Publication: 2021 Mar 25 (Print Publication: 2021).